Alpharma Asks Appeals Court To Remove Stay On Neurontin Capsule Launch

Law360 (September 13, 2004, 12:00 AM EDT) -- Generics maker Alpharma Inc. has asked an appeals court to lift its order to stay the U.S. Food and Drug Administration’s final approval of the company’s generic version of Pfizer's epilepsy treatment Neurontin.

If the stay is lifted, Alpharma plans to commence commercial sales of gabapentin capsules, the generic name of Neurontin, the company said in a statement.

Alpharma’s plans to start the commercial sales of gabapentin capsules are not contingent on the conclusion of the ongoing patent infringement case with Pfizer, according to the generics...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.